Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.

Introduction: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must have received docetaxel first, unless unsuitable for chemotherapy, despite no evidence suggesting superiority over androgen receptor signalling inhibitors (ARSIs).

Metabolic factors in diffuse idiopathic skeletal hyperostosis - a review of clinical data.

Objectives: We aimed to review the literature linking metabolic factors to Diffuse Idiopathic Skeletal Hyperostosis (DISH), in order to assess associations between growth factors and DISH.

Method: We identified studies in our personal database and PubMed using the following keywords in various combinations: "diffuse idiopathic skeletal hyperostosis", "ankylosing hyperostosis", "Forestier's disease", "diabetes", "insulin", "obesity", "metabolic", "growth factors", "adipokines", "glucose tolerance" and "chondrocytes".

Results: We were not able to do a systematic review due to variability in methodology of studies.